Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and safety of everolimus in the
treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic
chemotherapy. All patients were treated with everolimus until either tumor progression was
documented using a standard criteria that measures tumor size called Response Evaluation
Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the
patient or investigator requested discontinuation of treatment.